FDA Approves Aprepitant IV Injection for Post-Surgery Vomiting, Nausea Prevention


The approval is based on data from 2 clinical trials showing the agent improved the rate of post-operation patients avoiding sickness by 50%.

FDA Approves Aprepitant IV Injection for Post-Surgery Vomiting, Nausea Prevention

The US Food and Drug Administration (FDA) has approved aprepitant injectable emulsion (APONVIE) for the prevention of postoperative nausea and vomiting in adult patients.

The new approval makes the Heron Therapeutics agent the first and only intravenous (IV) form of aprepitant indicated for preventing nausea and vomiting in patients who underwent surgery. The single, 30-second, 32 mg IV injection dose has been shown to provide therapeutic plasma concentrations for ≥48 hours, according to Heron—providing an efficient response to increased risk of post-operative nausea and vomiting associated with 36 million surgeries conducted annually in the US.

Heron’s application to the FDA was supported by the results from a pair of multicenter, randomized, double-blind clinical trials comparing oral aprepitant to standard-care IV ondansetron injection, in patients at risk of post-operative sickness following open abdominal surgery. In the 48 hours following surgery, aprepitant was associated with 50% fewer patients vomiting than ondansetron. The oral form of the drug was also associated with a favorable tolerability and safety profile.

Approximately 3 in every 10 patients receiving general anesthesia experience post-operative sickness, which is among the greatest drivers of patient dissatisfaction with surgical procedures. It’s also associated with increased hospital stays and prolonged procedure recovery, Ashraf Habib, MBBCh, MSc, MHSc, chief of the division of women’s anesthesia at Duke University Hospital, said in a statement.

“Oral aprepitant has been used to prevent postoperative nausea and vomiting for more than 16 years and it is exciting to see that, with the approval of APONVIE, physicians can now offer patients a more convenient IV injection that delivers the same effective treatment, with a 48-hour duration of effect, in a rapid, consistent and reliable way, ensuring a better experience for patients postoperatively,” Habib said.

Barry Quart, PharmD, chairman and chief executive officer of Heron, said the new approval provides clinicians an “easy to use, highly effective option for these patients that fits seamlessly into our acute care franchise.”

Related Videos
Guillaume Lassailly: How Do We Value Bariatric Surgery in 2023?
Guillaume Lassailly: The Role of MASH, Fibrosis in Bariatric Surgery Survival
Better Fecal Live Microbiota Outcomes Linked to Gut Microbiome Health
Paul Feuerstadt, MD: Preventing Recurring C Difficile Infection in Older Adults with Comorbidities
Uma Mahadevan, MD: Prioritizing Gastric Health in Gestational Care
Brian Lacy, MD, PhD: Tailoring Treatment Experiences for IBS-C Patients
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Tenapanor Provides Varied Timing for IBS-C Symptom Relief
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Rene Gomez-Esquivel, MD: Screening for Pediatric Colon Cancer
© 2023 MJH Life Sciences

All rights reserved.